NNC 26-1187 | 267225-30-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: NNC 26-1187
• 英文别名: (2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-[(1R)-1-(N-methyl-N-{(1R)-1-[N-methyl-N-(2-(2-pyridinyl)ethyl)carbamoyl]-2-phenylethyl}carbamoyl)-2-(2-naphthyl)ethyl]amide；(2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-{N-methyl-N-[(1R)-2-phenyl-1-(N,N',N'-trimethylhydrazinocarbonyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)amide；(E)-5-amino-N,5-dimethyl-N-[(2R)-1-[methyl-[(2R)-1-[methyl(2-pyridin-2-ylethyl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide
• CAS: 267225-30-9
• 化学式: C₃₉H₄₇N₅O₃
• 分子量: 633.834
• InChiKey: HZNKEPLFTJARSS-UZVYAIDCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  47
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  99.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  ((3E)-1,1-Dimethyl-4-{N-methyl-N-[(1R)1-(N-methyl-N-{(1R)-1-[N-methyl-N-(2-(pyridin-2-yl)ethyl)carbamoyl]-2-phenylethyl}carbamoyl)-2-(2-naphthyl)ethyl]carbamoyl}but-3-enyl)carbamic acid tert-butyl ester 、 三氟乙酸 、 碳酸氢钠 、 水 在 ice 、 二氯甲烷 、 magnesium sulfate 、 crude product 、 silica 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 以in dichloromethane as eluent, to give 3.2 g of the title compound的产率得到NNC 26-1187
  参考文献：
  名称：

  Compounds with growth hormone releasing properties

  摘要：

  本发明涉及新型化合物、含有它们的组合物以及它们用于治疗由生长激素缺乏引起的医疗障碍的用途。

  公开号：

  US06566337B1

文献信息

• Compounds with growth hormone releasing properties
  申请人：Novo Nordisk A/S

  公开号：US06566337B1

  公开（公告）日：2003-05-20

  This invention relates to novel compounds, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.

  本发明涉及新型化合物、含有它们的组合物以及它们用于治疗由生长激素缺乏引起的医疗障碍的用途。
• COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES
  申请人：Novo Nordisk A/S

  公开号：EP1127071B1

  公开（公告）日：2004-08-04
• Growth Hormone Secretagogue Receptor Type 1A Agonists
  申请人：Andersen Bansholm Maibritt

  公开号：US20070066540A1

  公开（公告）日：2007-03-22

  Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.
• Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
  申请人：Polvino J. William

  公开号：US20070191283A1

  公开（公告）日：2007-08-16

  The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H 2 receptor antagonist, a serotonin 5-HT 4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.
• Method of treating cell proliferative disorders using growth hormone secretagogues
  申请人：Polvino William J.

  公开号：US20080207640A1

  公开（公告）日：2008-08-28

  The present invention relates to a method of treating cell proliferative disorders by administering to a subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.